What is Brainstorm Cell Therapeutics EV-to-Revenue?
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Brainstorm Cell Therapeutics's enterprise value is $11.93 Mil.
Brainstorm Cell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Brainstorm Cell Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Brainstorm Cell Therapeutics's EV-to-Revenue or its related term are showing as below:
BCLI's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.26 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Brainstorm Cell Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brainstorm Cell Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's EV-to-Revenue falls into.
Brainstorm Cell Therapeutics's current Enterprise Value is $11.93 Mil.
Brainstorm Cell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics's share price for today is $1.20.
Brainstorm Cell Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCLI has been successfully added to your 